28 Participants Needed

INTACT Program for Alzheimer's Disease

(INTACT Trial)

PJ
OZ
Overseen ByOdile Z Madesclaire, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Washington State University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems to focus on collecting data from patient records rather than changing treatments.

What data supports the effectiveness of the INTACT Program treatment for Alzheimer's disease?

The Alzheimer's and Dementia Care Program (ADC Program) is a comprehensive care model that has been effective in providing care for Alzheimer's disease, and similar structured education and follow-up interventions have shown positive outcomes for both patients and caregivers. Additionally, programs that include multimodal interventions have demonstrated promise in supporting and improving the quality of life for individuals in the early stages of Alzheimer's disease.12345

How is the INTACT Program treatment for Alzheimer's disease different from other treatments?

The INTACT Program is unique because it focuses on training caregivers and healthcare providers to improve care for Alzheimer's patients, rather than being a medication or direct medical intervention. This approach emphasizes education and skill-building to enhance the quality of care and support for individuals with Alzheimer's disease.16789

What is the purpose of this trial?

INTACT will utilize a group-randomized trial, to test the effectiveness of a culturally informed provider training and "dementia friendly clinic" intervention for detection and appropriate management of AI/AN patients with ADRD and MCI in 28 urban and rural clinics serving AI/ANs.

Eligibility Criteria

This trial is for healthcare providers in clinics serving American Indian/Alaska Native (AI/AN) communities. It aims to improve the detection and management of Alzheimer's Disease and related dementias (ADRD) as well as mild cognitive impairment (MCI).

Inclusion Criteria

Patients must be recorded as AI/AN in the EHR system
Primary care provider must have a title of MD, DO, Nurse Practitioner, or PA
I am 55 years old or older.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

The INTACT program is implemented, including PCP training, quarterly webinars, and a workflow model for cognitive evaluation

12 months
Quarterly webinars

Follow-up

Participants are monitored for safety and effectiveness after the intervention

12 months

Waitlist Control

Clinics in the wait-list arm will have the opportunity to receive the INTACT intervention after the initial 12-month study period

12 months

Treatment Details

Interventions

  • INTACT Program
Trial Overview The INTACT Program is being tested, which involves training providers and transforming clinics into 'dementia friendly' environments. The effectiveness will be measured across 28 urban and rural AI/AN-serving clinics.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: WaitlistExperimental Treatment1 Intervention
The INTACT Program has three components: 1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD, 2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia. 3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program
Group II: InterventionExperimental Treatment1 Intervention
The INTACT Program has three components: 1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD, 2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia. 3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington State University

Lead Sponsor

Trials
114
Recruited
58,800+

University of Miami

Collaborator

Trials
976
Recruited
423,000+

University of Washington

Collaborator

Trials
1,858
Recruited
2,023,000+

University of Minnesota

Collaborator

Trials
1,459
Recruited
1,623,000+

Findings from Research

The Alzheimer's and Dementia Care Program (ADC Program) is an effective model for comprehensive dementia care, but its implementation faces barriers that need to be addressed for wider adoption across the U.S.
Key factors for successful implementation include strong engagement from site leaders, the diverse roles of Dementia Care Specialists, and the necessity for adequate funding and support mechanisms to sustain comprehensive care over time.
Dissemination of a successful dementia care program: Lessons from early adopters.Lees Haggerty, K., Campetti, R., Stoeckle, RJ., et al.[2023]
The comprehensive care model for Alzheimer disease (AD) can lead to significant cost savings of $13 to $41 billion while improving the quality of care within 1-3 years of implementation, based on a study involving macroeconomic modeling and expert opinions.
Key components of the model include targeted outpatient chronic care management, cognitively protective acute care, and timely caregiver support, which together enhance patient experience and reduce overall healthcare spending by more than 15%.
Systems Delivery Innovation for Alzheimer Disease.Bott, NT., Sheckter, CC., Yang, D., et al.[2023]
A 12-week caregiver education and telephone follow-up intervention for caregivers of individuals with moderate Alzheimer's disease did not show statistically significant improvements in caregiver burden or patient symptoms compared to routine care.
Despite the lack of significant results, the study suggests that tailored education and support could still have potential benefits for managing caregiver stress and patient behavioral symptoms in the future.
The effect of structured education and phone follow-up on moderate stage Alzheimer's disease caregiving: Outcomes for patient and caregivers.Ozcan, M., Akyar, I.[2023]

References

Dissemination of a successful dementia care program: Lessons from early adopters. [2023]
Systems Delivery Innovation for Alzheimer Disease. [2023]
The effect of structured education and phone follow-up on moderate stage Alzheimer's disease caregiving: Outcomes for patient and caregivers. [2023]
Review of exemplar programs for adults with early-stage Alzheimer's disease. [2019]
Staff training in assisted living: evaluating treatment fidelity. [2021]
Caring for people with dementia in general hospitals: an education curriculum from the Alzheimer's Society of Lower Saxony, Germany. [2021]
Competency-based training for in-home supportive services providers of consumers with ADRD. [2020]
New directions for care of Alzheimer's disease and dementia. [2018]
Exemplars of successful Alzheimer's demonstration projects. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security